Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 604 trials

Advanced Non-Clear Cell Kidney Cancer: XL092 + Nivolumab

We are studying a new treatment combination for patients with advanced or metastatic non-clear cell kidney cancer. The goal is to see if it works better and is safer than the standard treatment.

Advanced Non-Clear Cell Renal Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Prostate Cancer: Apalutamide with Radiation Therapy

We are studying whether adding stereotactic body radiation therapy to Apalutamide improves treatment outcomes for men with low burden metastatic hormone-sensitive prostate cancer. This trial compares standard treatment alone to the combination therapy.

Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Asthma in Children: QMF149 vs. Budesonide

We are studying whether QMF149 can improve lung function and reduce asthma symptoms in children aged 6 to under 12 compared to Budesonide. This trial will help us understand which treatment works better for young patients.

Asthma6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsPulmonology

Acute Myeloid Leukemia: Comparing Treatment Regimens

We are studying two different conditioning regimens for adults with acute myeloid leukemia before stem cell transplantation. The goal is to see which regimen may improve survival and recovery outcomes.

Acute Myeloid Leukemia in Remission>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

Rheumatoid Arthritis: Precision Therapy Using Biomarkers

We are studying if tissue samples can help identify which RA patients will respond best to new biologic treatments. This may improve treatment outcomes for those who haven't benefited from standard therapies.

Rheumatoid ArthritisMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesRheumatology

Osteoporosis: Dasatinib and Quercetin Study

We are investigating whether a combination of dasatinib and quercetin can help improve bone health in patients with low bone mass. This study aims to see if it reduces bone loss more effectively than current treatments.

OsteoporosisOsteopenia3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Semaglutide for Glucose Intolerance in Women with Prior Gestational Diabetes

We are studying whether semaglutide can help women with a history of gestational diabetes manage glucose intolerance and reduce the risk of developing type 2 diabetes.

Prediabetes>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGynecology and Obstetrics

Kidney Disease: Iptacopan (LNP023) Study

We are testing a new medication for people with idiopathic immune complex mediated membranoproliferative glomerulonephritis to see if it reduces protein in urine and improves kidney function. The study also evaluates how well patients feel while using this treatment.

Idiopathic Immune Complex Mediated Membranoproliferative GlomerulonephritisConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Atopic Dermatitis: Amlitelimab Injection Study

We are evaluating the long-term safety and effectiveness of amlitelimab injections for individuals aged 12 and older with moderate to severe atopic dermatitis. This study aims to understand how the treatment impacts their symptoms and overall quality of life.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Achondroplasia: TransCon CNP Treatment

We are studying a new weekly injection for children and adolescents with achondroplasia to see if it is safe and helps improve growth. This trial will help us understand the long-term effects of this treatment.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Prostate Cancer: Metastasis-Directed Therapy Study

We are investigating if a new treatment can improve survival for men with castration-refractory prostate cancer and a few progressive lesions. This study compares the new approach to standard care to see which is more effective.

Oligoprogressive Metastatic Castration-Refractory Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Pramipexole for Anhedonic Depression

We are studying the long-term effects of adding pramipexole to treatment for people with anhedonic depression. The goal is to see how well it works and how well patients tolerate it.

Depression>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Open Angle Glaucoma: Citicoline Eye Drops

We are studying whether citicoline eye drops can help preserve vision in patients with open angle glaucoma. The trial also looks at the safety of these drops and their effects on eye structure.

Glaucoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Epilepsy: Long-term Study of XEN1101

We are examining the safety and effectiveness of XEN1101 for adults with epilepsy. This study looks at how well it reduces seizures and improves quality of life over time.

Generalized Tonic-Clonic SeizuresFocal Epilepsy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hydroceles and Spermatoceles: Comparing Sclerotherapy Treatments

We are studying two methods of sclerotherapy to see which one better reduces symptoms and requires fewer follow-up treatments. This trial also looks at pain levels during the procedure with and without local anesthesia.

SpermatoceleHydrocele>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesUrology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Small Cell Lung Cancer: Trilaciclib vs Placebo

We are studying whether trilaciclib can improve survival for patients with extensive stage small cell lung cancer receiving chemotherapy. The trial will also assess its effects on tumor response and safety compared to a placebo.

Extensive Stage Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Methylmalonic Acidemia: mRNA-3705 Treatment Study

We are testing a new treatment, mRNA-3705, for individuals with isolated Methylmalonic Acidemia. The study aims to evaluate its safety and how well it lowers harmful acid levels in the blood.

Methylmalonic Aciduria>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Non-Hodgkin Lymphoma: GLPG5101 Treatment Study

We are evaluating a new treatment called GLPG5101 for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to understand its safety and effectiveness compared to existing options.

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Neuroendocrine Tumors: SAUNA Trial on Somatostatin Analogues

We are studying whether continuing or stopping somatostatin analogues affects survival and quality of life in patients with neuroendocrine tumors after disease progression. This trial aims to provide insights into the best treatment strategies for these patients.

Neuroendocrine Tumors1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology